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Factors Inﬂuencing Pulmonary Toxicity in the Setting of
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Purpose: To evaluate factors associated with increased risk
of pulmonary toxicity in pediatric patients after myeloab-
lative conditioning using total body irradiation (TBI) fol-
lowed by allogeneic hematopoietic stem cell transplantation
(HSCT).
Methods and materials: The records of 129 consecutive
pediatric patients (range, 1-21 years) who underwent TBI-
based myeloablative conditioning for hematologic malig-
nancies at our institution between January 2003 and May
2014 were reviewed. Although total TBI dose ranged from
10.5 to 14Gy, lung doses were reduced to 10Gy with partial
transmission blocks. The TBI dose rate ranged from 5.57cGy/
min to 20.85cGy/min.
Results: Pulmonary toxicity developed in 70.5% of patients,
which proved to be fatal in 38.5% of those patients. Patients
with any type of infection at any point during the follow-up
period were more likely to develop pulmonary toxicity
(p¼0.009), and patients with bacterial infection during the
follow-up period had the highest incidence of pulmonary
toxicity (p¼0.038). The presence of any grade of acute graft-
versus-host-disease (GVHD) was associated with an
increased incidence of pulmonary toxicity (p¼0.034), which
developed in 94.4% of patients with grade III-IV GVHD
(p¼0.001). TBI dose rate was signiﬁcantly related to the
development of pulmonary toxicity (p¼0.0495). Pulmonary
toxicity was 3.51 times more likely to develop in patients
receiving a TBI dose rate greater than 15cGy/min (p¼0.017).
Overall survival was signiﬁcantly shorter in patients who
developed pulmonary toxicity (p¼0.0053).
Conclusions: A high incidence of pulmonary toxicity was
noted in this large series of homogeneously treated pediatric
patients undergoing TBI for allogeneic HSCT. The presence of
high grade acute GVHD and infection were the most signif-
icant factors contributing to the development of pulmonary
toxicity. TBI dose rate should be aimed to be kept below
15cGy/min to decrease the risk of pulmonary injury.377
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Research Centre, Delhi, IndiaHigh cost of matched unrelated donor stem cells limits its use
in resource poor countries. Haploidentical donor is readily
available for most of patients and at much lower cost, so can
be feasible for poor patients. Here, we are reporting the
outcome of 19 patients (16 male, 3 female), median age 37
years(15-63 yrs), who underwent Haplo HSCT using periph-
eral blood stem cells(n¼16) and marrow (n¼3) during
October 2011 to September 2014 at Rajiv Gandhi Cancer
Institute & Research Centre (India) using non-myeloablative
(NMA) and reduced intensity conditioning regimen (RIC) for
hematological disorders (AA¼2,ALL¼4,AML¼5,NHL¼1,HL¼2,
MM¼1,CML¼5) with post-transplant cyclophosphamide for
GvHD prophylaxis. Fourteen patients were in remission at the
time of transplant. Seven patients received RIC with
BuFluCy(n¼5) and BuFlu(n¼2), 12 patients received NMA
conditioning with FluCyATG(n¼3) and FluCyTBI(n¼9). Me-
dian CD34 cell dose was 5 X10⁶cells/kg. Fifteen patients (79%)
were engrafted, with a median time to neutrophil engraft-
ment of 15 days (range, 9-22) and platelet engraftment of 14
days (range, 10-46). Nine patients had documented bacterial
infection in ﬁrst 100 days whereas none had documented
fungal infection. Primary and secondary CMV reactivation
occurred in 7 (36.8%) and 2 (10.5%) patients. The estimated
day 100 and 1 year overall survival (OS) was 84.20.84% &
52.10.127 % respectively. The estimated 1 year event free
survival (EFS) & non-relapse mortality (NRM) was
48.40.123% & 26.3%. Cumulative incidence of aGVHD (II-IV)
and (III-IV) was 26.3% & 5.2%whereas cumulative incidence of
chronic GVHD at 1 year & 2 year was 15.8% & 10.5% respec-
tively. Graft rejectionwas seen in 6 patients (31.5%, 5 primary
and 1 secondary). These results suggest that this approach is
safe & effective, with rapid multilineage engraftment, low
rates of both aGVHD & cGVHD and low NRM.378
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In previous studies using a preparative regimen of ﬂudar-
abine (Flu) plus high-dose cyclophosphamide (Cy; total
dose, 4800 mg/m2) and GVHD prophylaxis of cyclosporine
plus methotrexate, it was determined that transplant
recipients had quite variable plasma levels of the T cell
